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number of comorbidities.
Methods: The current study included 300 COPD patients aged 65.28 ± 6.32 years, 148 of them
(49.3%) were females and the rest were males and 300 control age and gender matched patients with
diseases other than COPD; aged 64.70 ± 7.12 years, 138 of them (46%) were males and the rest
were females. They were enrolled in the study during their follow up visits to the outpatient clinic
of the Chest Department, Menouﬁya University Hospitals from August 2009 to August 2012. The
GFR was estimated and patients were categorized according to their renal function as having nor-
mal renal function (GFRP 60 mL/min/1.73 m2), concealed CRF (normal serum creatinine and
GFR< 60 mL/min/1.73 m2), or overt CRF (increased serum creatinine and GFR< 60 mL/min/
1.73 m2).
Results: In the COPD group; the mean BUN value was 22.86 ± 13.63, the mean serum creati-
nine concentration was 1.29 ± 0.67 mg/dL and the mean estimated GFR was 75.20 ± 35.78 mL/
min/1.73 m2. In the control group; the mean BUN value was 14.04 ± 9.61, the mean serum creat-
inine concentration was 0.85 ± 0.34 mg/dL and the mean estimated GFR was 92.04 ± 25.54 mL/
min/1.73 m2 (P< 0.01 for all in comparison with the COPD group). The prevalence of normal
renal function, concealed CRF, and overt CRF in COPD group of patients was 54%, 26% and
20%, respectively. The corresponding ﬁgures in the control group were 78%, 10%, and 12%,
respectively (COPD vs control group: P< 0.001). The overall prevalence of CRFive pulmonary disease; CRF,
ﬁltration rate (GFR); GOLD,
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222 I.I. Elmahallawy, M.A Qora(GFR< 60 mL/min/1.73 m2) was 46% in the study group and 22% in the control group
(P< 0.001). COPD was signiﬁcantly associated with both concealed and overt CRF. Age and
hypoalbuminemia were signiﬁcantly associated with overt CRF while the number of comorbidities
was signiﬁcantly associated with concealed CRF.
Conclusions: CRF may be an important COPD comorbidity and should be screened for not only
by serum creatinine level but also by the estimated GFR.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is actually the
fourth leading cause of chronic morbidity and mortality world-
wide. Mortality from COPD is expected to increase further
and to rank at the third position in 2020, after coronary artery
disease and stroke [1].
COPD is deﬁned as a preventable and treatable disease with
signiﬁcant extrapulmonary effects that may contribute to its
severity in individual patients. Comorbidities such as chronic
heart failure, cardiovascular disease, depression, diabetes, mus-
cle wasting, weight loss, lung cancer, and osteoporosis can fre-
quently be found in patients with COPD and are considered to
be part of the commonly prevalent non-pulmonary sequelae of
the disease [2].
Cardiovascular disease and lung cancer play an important
role for mortality in mild and severe COPD. Weight loss and
loss of fat-free mass have an impact on prognosis in patients
with COPD. Depressive symptoms in patients with COPD
are associated with poorer survival, longer hospital stay, in-
creased symptom burden, and poorer physical and social func-
tioning. Left heart dysfunction is independently associated
with reduced physical activity in patients with COPD of differ-
ent severity [3,4].
Chronic renal failure (CRF) rises in prevalence with age and
is frequently associated with chronic diseases such as congestive
heart failure and diabetesmellitus.When present as a comorbid-
ity, CRF carries negative prognostic implications and impacts
the therapeutic strategy [5]. It is unknown towhich extentCOPD
is associated with CRF and the relationship between renal fail-
ure and COPD is largely undescribed. A proportion of patients
with COPD has a reduced muscular mass, and thus, serum cre-
atininemight be falsely low as the result of decreased creatine re-
lease. Also, CRF may be associated with normal serum
creatinine concentration, a condition known as unrecognized
or concealed CRF. It is diagnosed by glomerular ﬁltration rate
(GFR) < 60 mL/min/1.73 m2. The purpose of the current study
was to estimate the frequency of undiagnosed renal failure in a
population of COPD patients [6].Materials and methods
The current study included 300 COPD patients aged
65.28 ± 6.32 years, 148 of them (49.3%) were females and
the rest were males and 300 control age and gender matched
patients with diseases other than COPD; aged
64.70 ± 7.12 years, 138 of them (46%) were males and the rest
were females. They were enrolled in the study during their fol-
low up visits to the outpatient clinic of the Chest Department,
Menouﬁya University Hospitals from August 2009 to August2012. All patients in both groups were in a stable condition
and with no physical ﬁndings or symptoms suggestive of acute
exacerbation or therapy modiﬁcations in the 30 days before
enrollment. A written consent was obtained from each patient
participating in this study.
All participants included in the study performed prebron-
chodilator and postbronchodilator spirometry according to
American Thoracic Society (ATS) criteria [7]. Separate mea-
surements were made before and at least 15 min after two puffs
of Salbutamol (200 mg) administered with a metered dose in-
haler with volumatic spacer. Irreversible airway obstruction
was deﬁned as a postbronchodilator FEV1/FVC< 0.7
according to the GOLD (Global Initiative for Obstructive
Lung Disease) guidelines and the FEV1 was used to further
stage the disease: mild (GOLD stage I, FEV1 pre-
dictedP 80%), moderate (GOLD stage II, 50% 6 FEV1 pre-
dicted < 80%), severe (GOLD stage III, 30% 6 FEV1
predicted < 50%) and very severe (GOLD stage IV, FEV1 pre-
dicted < 30% or 30% 6 FEV1 predicted < 50% in the pres-
ence of corpulmonale or respiratory failure) [8].
The GFR was estimated using the Modiﬁcation of Diet in
Renal Disease (MDRD) Study Group equation:
170 ½serum creatinine0:999  ½age0:176  ½blood urea0:170
½serum albumin0:318ð0:762 for womenÞ ð1:180 for African-
American subjectsÞ [9]. Patients were categorized according to
their renal function as having normal renal function
(GFRP 60 mL/min/1.73 m2), concealed CRF (normal serum
creatinine and GFR< 60 mL/min/1.73 m2), or overt CRF (in-
creased serum creatinine and GFR< 60 mL/min/1.73 m2)
[10]. The cutoff used for serum creatinine was 1.26 mg/dL in
men and 1.04 mg/dL in women [11].
Statistical analysis
– Data was statistically analyzed using SPSS (statistical pack-
age for social science) program version 13 for windows and
a P value < 0.05 was considered statistically signiﬁcant.
– ANOVA test was done to compare more than two
variables.
– Multivariate logistic regression analysis was performed on
factors which were signiﬁcantly different in a uni-variate
analysis between patients of both groups (COPD and con-
trol groups) in order to determine adjusted Odds ratio
(OR) and 95% conﬁdence interval (CI) to detect the factors
that are independently associated with the presence of CRF.
Results
The current study included 300 COPD patients and 300 con-
trol and gender matched patients with diseases other than
Table 1 Diseases of the control group.
Groups Frequency Percent
Non COPD patients (controls)
RHD 18 6.0
TB 18 6.0
ILD 48 16.0
Pleural eﬀusion 12 4.0
BA 60 20.0
CHF 24 8.0
OHS 18 6.0
Lung cancer 12 4.0
OSA 24 8.0
RA 18 6.0
IHD 6 2.0
Pneumonia 36 12.0
SLE 6 2.0
Total 300 100.0
Prevalence of chronic renal failure in COPD patients 223COPD. The main diseases in the control group are shown in
Table 1. The most common disease was BA (n= 60, 20%) fol-
lowed by ILD (n= 48, 16%) and pneumonia (n= 36, 12%).
Table 2 shows the co-morbidities in the COPD and the control
groups; the most common co-morbidity in both groups was
DM.
The mean age of the COPD group was 65.28 ± 6.32 years,
50.7% of them were males (n= 152) while 49.3% were females
(n= 148). The BMI was 29.89 ± 8.63 kg/m2. The smoking in-
dex among the COPD patients was 25.66 ± 10.99 pack-years.
The mean FEV1 of the studied COPD patients was
48.14%± 14.24. According to the GOLD classiﬁcation;
18% (n= 54) of them had moderate COPD (stage II), 10%
(n= 30) had severe COPD (stage III) and 72% (n= 216)
had very severe COPD (stage IV). Corpulmonale was present
in 54% (n= 162) of them while chronic type II respiratoryTable 2 Comorbidities in the COPD and the control groups.
Comorbidity
No comorbidity Count % within Groups
HTN Count % within Groups
DM Count % within Groups
HTN & DM Count % within Groups
CLD & HTN Count % within Groups
CLD & DM Count % within Groups
DM & HTN & CLD Count % within Groups
IHD Count % within Groups
CLD Count % within Groups
Total
Count % within Groupsfailure was present in 68% (n= 204) of the studied COPD pa-
tients. The mean BUN value was 22.86 ± 13.63, the mean ser-
um creatinine concentration was 1.29 ± 0.67 mg/dL and the
mean estimated GFR was 75.20 ± 35.78 mL/min/1.73 m2.
The mean age of the control group was 64.70 ± 7.12 years
and 46% of them were males (n= 138) while 54% were fe-
males (n= 162) [P> 0.05 for age and sex in comparison with
the COPD group]. The BMI was signiﬁcantly higher than that
in the COPD group [32.31 ± 11.81, (P< 0.01)]. Regarding
the renal function; the mean BUN value was 14.04 ± 9.61,
the mean serum creatinine concentration was
0.85 ± 0.34 mg/dL and the mean estimated GFR was
92.04 ± 25.54 mL/min/1.73 m2 (P< 0.01 for all in compari-
son with the COPD group). No signiﬁcant difference was
found between both groups regarding either the Hb% or the
albumin level (P< 0.05) Tables 3 and 4.
The prevalence of normal renal function, concealed CRF,
and overt CRF in COPD group of patients was 54%, 26%
and 20%, respectively. The corresponding ﬁgures in the con-
trol group were 78%, 10%, and 12%, respectively (case vs con-
trol group: P< 0.001). The overall prevalence of CRF
(GFR< 60 mL/min/1.73 m2) was 46% in the study group
and 22% in the control group (P< 0.001).
Demographic, clinical and laboratory characteristics of pa-
tients with COPD grouped according to whether they had nor-
mal renal function, concealed CRF, or overt CRF are reported
in Table 5. Patients with concealed CRF were more frequently
males [50% vs 44%, (P> 0.05)], were older in age
[65.50 ± 4.70 vs 63.17 ± 5.31 years, (P> 0.05)], had lower
FEV1 [38.50 ± 3.66 vs 56.83 ± 10.59, (P< 0.01)], had higher
smoking index [27.00 ± 15.67 vs 22.23 ± 9.20 pack-years,
(P< 0.01)], had more comorbidities [100% vs 68%,
(P< 0.01)], had lower BMI [28.78 ± 7.59 vs 30.64 ±
9.29 kg/m2, (P> 0.05)], had lower albumin level [3.32 ±
0.99 vs 3.65 ± 0.53, (P< 0.01)] and had lower Hb%Groups
COPD patients Non COPD patients (controls)
72
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Table 4 Gender differences between studied groups.
Gender Groups X2 test p-value
COPD patients (n= 300) Non COPD (n= 300)
No % No %
Male 152 50.7 138 46.0 1.31 >0.05
Female 148 49.3 162 54.0
Table 5 Demographic, clinical and laboratory characteristics of patients divided according to renal function.
Characteristics Normal Renal Function,
n= 162
Concealed renal
dysfunction, n= 78
Overt renal dysfunction,
n= 60
P value
Age (years): 63.17 ± 5.31 65.50 ± 4.70 68.89 ± 6.44a,b <0.01
Gender, males 71 (44%) 39 (50%) 42 (70%)a,b <0.01
FEV1% 56.83 ± 10.59 38.50 ± 3.66a 34.72 ± 7.65b <0.01
Pack-years 22.23 ± 9.20 27.00 ± 15.67a 32.56 ± 9.50a,b <0.01
Comorbidities, n 110 (68%) 78 (100%)a 56 (93%)a <0.01
BMI, kg/m2 30.64 ± 9.29 28.78 ± 7.59 26.11 ± 7.39 >0.05
Serum albumin,
3.5 g/dL
3.65 ± 0.53 3.32 ± 0.99a 2.74 ± 0.72a,b <0.01
Hb% 13.17 ± 1.87 13.05 ± 1.04 13.00 ± 2.02 >0.05
a P< 0.001 vs normal renal function.
b P< 0.001 vs concealed CRF.
Table 3 Differences between both groups regarding all the studied variables.
Variables Groups Mean ± SD t- test P value
Age COPD patients 65.28 ± 6.32 1.06 >0.05
Non COPD patients (controls) 64.70 ± 7.12
Weight COPD patients 79.60 ± 13.72 0.29 >0.05
Non COPD patients (controls) 84.90 ± 30.59
Height COPD patients 165.78 ± 14.94 2.68 >0.05
Non COPD patients (controls) 163.90 ± 11.16
BMI COPD patients 29.89 ± 8.63 2.84 <0.01
Non COPD patients (controls) 32.31 ± 11.81
Hb COPD patients 12.95 ± 1.94 0.58 >0.05
Non COPD patients (controls) 12.87 ± 1.38
Albumin COPD patients 3.35 ± 0.70 0.97 >0.05
Non COPD patients (controls) 3.40 ± 0.61
BUN COPD patients 22.86 ± 13.63 10.52 <0.01
Non COPD patients (controls) 14.04 ± 9.61
Creatinine COPD patients 1.29 ± 0.67 8.89 <0.01
Non COPD patients (controls) 0.85 ± 0.34
GFR COPD patients 75.20 ± 35.78 6.43 <0.01
Non COPD patients (controls) 92.04 ± 25.54
224 I.I. Elmahallawy, M.A Qora[13.05 ± 1.04 vs 13.17 ± 1.87, (P> 0.05)] when compared
with those who had normal renal function.
Patients with overt CRF were more frequently males than
those with concealed CRF and normal renal function [70%
vs 50% vs 44% respectively, (P< 0.01)], were older in age
[68.89 ± 6.44 vs 65.50 ± 4.70 vs 63.17 ± 5.31 years respec-
tively, (P< 0.01)], had lower FEV1 [34.72 ± 7.65 vs
38.50 ± 3.66 vs 56.83 ± 10.59 respectively, (P< 0.01)], hadhigher smoking index [32.56 ± 9.50 vs 27.00 ± 15.67 vs
22.23 ± 9.20 pack-years respectively, (P< 0.01)], had lower
BMI [26.11 ± 7.39 vs 28.78 ± 7.59 vs 30.64 ± 9.29 kg/m2
respectively, (P> 0.05)], had lower albumin level
[2.74 ± 0.72 vs 3.32 ± 0.99 vs 3.65 ± 0.53 respectively,
(P< 0.01)], and had lower Hb% [13.05 ± 1.04 vs
13.17 ± 1.87, (P> 0.05)] than those with concealed CRF
and normal renal function. Patients with overt CRF had more
Table 6 Backward stepwise logistic regression models of
selected variables to concealed or overt renal dysfunction vs
normal renal function.
Variables OR 95% CI
Concealed renal dysfunction
Co morbidity 46.69 52.24–17.58
COPD 15.49 32.83–9.11
Overt renal dysfunction
Age, year (for each 1-year increase) 3.76 2.05–6.91
Albumin <3.5 3.94 2.26–6.88
COPD 3.41 1.91–6.11
Prevalence of chronic renal failure in COPD patients 225comorbidities than those with normal renal function [93% vs
68%, (P< 0.01)] but less than those with concealed CRF
[93% vs 100%, (P> 0.05)].
Independent correlates of concealed or overt CRF in the
general sample (i.e., pooled cases and controls) are reported
in Table 6. COPD was signiﬁcantly associated with both con-
cealed and overt CRF. Age and hypoalbuminemia were signif-
icantly associated with overt CRF while the number of
comorbidities was signiﬁcantly associated with concealed
CRF. Logistic regression analysis identiﬁed the number of
comorbidities (OR: 46.69 & 95% CI: 52.24–17.58) and COPD
(OR: 15.49 & 95% CI: 32.83–9.11) as signiﬁcant correlates of
concealed CRF; and identiﬁed age (OR: 3.76 & 95% CI: 2.05–
6.91), hypoalbuminemia (OR: 3.94 & 95% CI: 2.26–6.88), and
COPD (OR: 3.41 & 95% CI: 1.91–6.11) as independent corre-
lates of overt CRF.Discussion
The main ﬁnding of this study is the high prevalence of CRF
(concealed and overt) among patients with COPD. About half
of the COPD patients have CRF and one of each four COPD
patients has CRF despite normal serum creatinine. The overall
prevalence of CRF (GFR< 60 mL/min/1.73 m2) was 46% in
the COPD group (26% concealed CRF and 20% overt CRF)
and 22% in the control group (10% concealed CRF and 12%
overt CRF) (P< 0.001). While serum creatinine greater than
1.26 mg/dL for men and 1.04 mg/mL for women is a reliable
marker of CRF [11], the GFR is frequently depressed in pa-
tients with COPD despite normal serum creatinine [26% of
COPD patients have low GFR despite normal serum creati-
nine (concealed CRF) in comparison with 10% in the control
group].
Regarding the renal function parameters, the mean BUN
value, the mean serum creatinine concentration and the mean
estimated GFR were signiﬁcantly worse in the COPD group in
comparison with the control group (P< 0.01 for all).
Logistic regression analysis showed that COPD was signif-
icantly associated with both concealed and overt CRF, age and
hypoalbuminemia were signiﬁcantly associated with overt
CRF and the number of comorbidities was signiﬁcantly asso-
ciated with concealed CRF.
Despite the huge number of comorbidities associated with
COPD, few studies have assessed the prevalence of CRF
among COPD patients. In 1997, among 270 consecutive italian
COPD patients admitted in the Pneumology ward of theCatholic University in Rome between the years 1980–1990,
for an acute exacerbation of COPD, Antonelli Incalzi and col-
leagues [6] found that 6% had CRF (deﬁned by an abnormal
serum creatinine), they had a shorter survival time than those
without CRF (0.8 vs 3.2 years; p= 0.002). Some years later,
the same group assessed 365 COPD outpatients aged 65 years
and older attending the pulmonary medicine outpatient facili-
ties of 15 participating centers located throughout Italy and as-
signed them to one of three groups; normal renal function,
concealed CRF (normal creatinine with low estimated GFR)
and overt CRF (abnormal serum creatinine). The prevalence
of CRF was 43% (20.8% concealed CRF and 22.2% overt
CRF) in the COPD group compared with 23.4% (10.0% con-
cealed CRF and 13.4 overt CRF) in another group of hospital
outpatients (control group). COPD patients were 2.19 times
more likely to have concealed CRF and 1.94 times more likely
to have overt CRF than controls [7].
Lower ﬁgures were found by Gjerde and collegues [13] who
studied the prevalence of undiagnosed renal failure in COPD
patients in western Norway. They found that the prevalence
of having CRF (GFR< 60 mL/min/1.73 m2) was 9.6% in fe-
male COPD patients and 5.1% in male COPD patients.
A much lower percentage of CRF in COPD patients was re-
ported by Van Manen et al. [14] who found that the diagnosis
of kidney disease was self reported by only 0.2% of patients
with COPD.
In a large multinational survey addressing the impact of
COPD in North America and Europe in 2000, done by Ren-
nard and colleagues [15]; 11.3% of participating COPD pa-
tients were found to have CRF. Gestel et al. [16] studied the
association between COPD and chronic kidney disease
(CKD) in 3358 patients underwent elective vascular surgery
between January 1990 and December 2006 in the Netherlands.
They found that COPD was associated with a higher risk of
prevalent CKD. After adjustment for other factors, patients
with COPD had increased odds of CKD (adjusted OR: 1.22
& 95% CI: 1.03–1.44 & P= 0.03). A borderline signiﬁcant
relationship was observed for mild COPD while moderate
COPD was independently associated with kidney disease
(OR: 1.23 & 95% CI: 0.99–1.53 & P= 0.06 and OR: 1.33 &
95% CI 1.07–1.65 & P= 0.01 respectively). Also, Chandra
et al. [17] found a signiﬁcant association between radiograph-
ically measured emphysema in COPD patients and GFR; par-
ticipants with 10% more emphysema had GFR which was
lower by 4.4 ml/min/1.73 m2 (P= 0.01).
The association between COPD and CRF may be explained
by several factors. First; it was found that arteriolar renal resis-
tances are increased in COPD patients, perhaps because of lo-
cal adrenergic discharge secondary to hypercapnia. In the
initial phase of COPD, renal perfusion is usually normal, but
as the disease worsens, particularly as CO2 retention develops,
renal blood ﬂow decreases. PaCO2 has been found to correlate
inversely with ERPF (effective renal plasma ﬂow) and with the
ability to excrete sodium and water. Hypercapnia may cause
renal vasoconstriction directly and indirectly by stimulating
sympathetic tone as detected by the increase in the circulating
levels of norepinephrine [12–21].
Second; both nicotine and selected heavy metals as lead and
cadmium, which are components of smoke, are risk factors for
CRF. Nicotine causes nephropathies with an increased inci-
dence of microalbuminuria progressing to proteinuria [22].
Lead and cadmium cause nephrotoxicity in the form of tubular
226 I.I. Elmahallawy, M.A Qoraproteinuria and glomerular dysfunction evidenced by an in-
creased excretion of high molecular weight proteins and in-
creased levels of creatinine in plasma, and giving rise to a
glomerular type proteinuria [23–25].
Third; COPD is generally recognized as a cause of sys-
temic inﬂammation. Pro-inﬂammatory cytokines, especially
tumour necrosis factor-alpha (TNF-a), play an important
role in the disease process. This systemic inﬂammatory state
in patients with COPD is associated with the increased risk
of cardiac injury. In addition to pulmonary inﬂammation,
several other parts of the body are affected resulting in mus-
cle wasting, weight loss, diabetes, osteoporosis, atherosclero-
sis and renal dysfunction. So the systemic inﬂammation
seen in patients with COPD might explain the association be-
tween COPD and CRF [26,27]. Also, as a result of the muscle
wasting and reduced muscular mass frequently occurring in
COPD patients; serum creatinine might be falsely low as
the result of decreased creatine release and the GFR may
be reduced despite normal creatinine concentration (con-
cealed CRF) [7].
Fourth; pulmonary hypertension secondary to COPD, may
be associated with the progression of kidney disease [16]. Fifth;
coronary artery disease, which is highly prevalent in patients
with COPD, is associated with vascular kidney disease [28].
This high prevalence of CRF found in COPD patients
might explain the association between COPD and a large num-
ber of other comorbidities. First; renal impairment is expected
to be associated with decreased activity of renal a 1-hydroxy-
lase with subsequent lower levels of the mean serum 25-
hydroxyvitamin D than those with normal renal function. This
may be an important factor underlying the association be-
tween COPD and osteoporosis [29,30].
Second, the prevalence of anemia in COPD patients is
thought to be secondary to chronic inﬂammation and to a les-
ser extent to iron and folate deﬁciencies [31]. CRF may be an
important underlying cause of anemia through impaired pro-
duction of erythropoietin [32]. Third, CRF is associated with
increased serum levels of inﬂammatory biomarkers and pro-
thrombotic molecules. Thus, CRF may add to the factors
explaining the association between COPD and cardiovascular
diseases [33]. Finally, most drugs commonly used in treatment
of COPD exacerbations and comorbidities are water soluble
and cleared by the kidney. As a result, the association between
COPD and CRF will make COPD patients at higher risk for
adverse drug reactions to water soluble drugs and drug pre-
scribing and dosing should be adjusted [34].
In conclusion, CRF is an important COPD comorbidity
and should be screened for not only by serum creatinine level
but also by the estimated GFR to recognize the cases of con-
cealed CRF who have low GFR despite normal serum creati-
nine level.References
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